

Reference:	FOI.9078.22
Subject:	Use of somatropins
Date of Request:	31 May 2022

Requested:

a. How many patients have you treated in the last 12 months with the following drugs?

- Genotropin
- Humatrope
- Norditropin
- Nutropin
- Omnitrope
- Saizen
- Zomacton
- Any other Somatropin (please specify)

b. Please provide the number of patients under the age 16 that were treated in the last 12 months with each of the following drugs:

- Genotropin
- Humatrope
- Norditropin
- Nutropin
- Omnitrope
- Saizen
- Zomacton

Response:

a. and b. Hywel Dda University Health Board (UHB) provides, within the table below, the total number of patients and those under the age of sixteen (16), treated with the listed medications, during the period 1 June 2021 to 31 May 2022.

Medication	Total number of patients	Number of patients aged under 16
Genotropin	*	0
Humatrope	*	0
Norditropin	16	*
Nutropin	0	0
Omnitrope	*	*
Saizen	*	*
Zomacton	0	0
Any other Somatropin (please specify)	0	

Where the figures in the tables have been replaced with an asterisk (*), the UHB is unable to provide you with the exact number of patients, due to the low number of cases (5 and under), as there is a potential risk of identifying individuals if this was disclosed. The UHB is therefore withholding this detail under Section 40(2) of the Freedom of information Act 2000 (FoIA).

This information is protected by the Data Protection Act 2018 and the UK General Data Protection Regulations (UK GDPR), as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles 6 and 9 of the UK GDPR. This exemption is absolute and therefore, there is no requirement to apply the public interest test.

In reaching this decision, the Data Protection Act 2018/UK GDPR define personal data as data which relates to a living individual who can be identified solely from that data, or from that data and other information, which is in the possession of the data controller.